Scientists from premier institutions such as Indian Institute of Technology-Bombay, Bhabha Atomic Research Centre, Indian Council for Medical Research and Haffkine institute and National Institute of Immuno Haematology would showcase their research in Homoeopathy at a two-day World Summit to be held here from April 11.
Researches by India's premier institutes presented at a press conference here yesterday show that Homoeopathy has given rise to a new hope to patients suffering from dreaded HIV, tuberculosis and the deadly blood disease Hemophilia.
In a pioneering two-year long study, city-based homoeopath Dr Rajesh Shah has developed a new medicine for AIDS patients, sourced from human immunodeficiency virus (HIV) itself.
The drug has been tested on humans for safety and efficacy and the results are encouraging, said Dr Shah. Larger studies with and without concomitant conventional ART (Antiretroviral therapy) can throw more light in future on the scope of this new medicine, he said.
Dr Shah's scientific paper for debate has just been published in Indian Journal of Research in Homoeopathy (IJRH), the Official publication of the Central Council for Research in Homoeopathy (CCRH) in its online edition. CCRH is a Union Government-run institute.
The drug resulted in improvement of blood count (CD4 cells) of HIV patients, which is a very positive and hopeful sign, he said and expressed the hope that this will encourage an advanced research into the subject.
Sourcing of medicines from various virus and bacteria has been a practise in the homoeopathy stream long before the prevailing vaccines came into existence, said Dr Shah, who is also organising secretary of Global Homoeopathy Foundation (GHF), an NGO, and holds a Limca Book record for treating patients from 180 countries.
Dr Shah, who has been campaigning for the integration of homoeopathy and allopathic treatments, said this combination has proven to be useful for several challenging diseases. He teamed up with noted virologist Dr Abhay Chowdhury and his team at the premier Haffkine Institute and developed a drug sourced from TB germs of MDR-TB patients.
